advertisement
Abstract #106757 Published in IGR 23-3
Acetazolamide-Induced Periorbital Myokymia: A Case Report
Raj A; Alapatt PJ; Johny P; K P A; V V ACureus 2022; 14: e31920
Acetazolamide, a carbonic anhydrase inhibitor, is primarily used in the treatment of glaucoma, due to its role in decreasing intraocular pressure by lowering the production of aqueous humor. Additionally, by lowering cerebrospinal fluid (CSF) production, it is also used in the treatment of raised intracranial pressure. Drug-induced myokymia has rarely been reported, with known triggers being clozapine, gabapentin and flunarizine, and topiramate. Acetazolamide-induced myokymia itself has only been reported once before, to the best of our knowledge, and the exact mechanism behind this occurrence remains unknown. We, therefore, report a rare case of periorbital myokymia induced by the use of acetazolamide in a patient diagnosed with idiopathic intracranial hypertension. The nature of her symptoms was significant, as they caused her considerable distress, and subsided almost immediately upon discontinuation of the drug.
Department of Neurology, Aster Malabar Institute of Medical Sciences (MIMS), Kozhikode, IND.
Full article